Shengxiang Ren, Anwen Xiong, Jia Yu, Xicheng Wang, Baohui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou
BACKGROUND: The combination of immune checkpoint inhibitors and antiangiogenic agents has been effective in treating multiple cancers. This was further explored in an open-label, multicenter phase 2 basket study (NCT04346381), which evaluated the antitumor activity and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) in patients with advanced solid tumors. We herein report the findings from the cohort of advanced NSCLC patients who progressed after treatment with platinum-doublet chemotherapy and immunotherapy...
May 10, 2024: Cancer Immunology, Immunotherapy: CII